Hao‐Yuan Mo
About
Hao‐Yuan Mo is a scholar working on Otorhinolaryngology, Oncology and Surgery.
According to data from OpenAlex, Hao‐Yuan Mo has authored 37 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Otorhinolaryngology, 24 papers in Oncology and 17 papers in Surgery. Recurrent topics in Hao‐Yuan Mo's work include Head and Neck Cancer Studies (28 papers), Head and Neck Surgical Oncology (12 papers) and Viral-associated cancers and disorders (11 papers). Hao‐Yuan Mo is often cited by papers focused on Head and Neck Cancer Studies (28 papers), Head and Neck Surgical Oncology (12 papers) and Viral-associated cancers and disorders (11 papers). Hao‐Yuan Mo collaborates with scholars based in China, Sweden and United States. Hao‐Yuan Mo's co-authors include Hai‐Qiang Mai, Ming‐Huang Hong, Tai‐Xiang Lu, Jun Ma, Nian‐Ji Cui, Hua-Qing Min, Qiuyan Chen, Yi‐Xin Zeng, Xiang Guo and Ling Guo and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer.
In The Last Decade
Hao‐Yuan Mo
36 papers receiving 1.2k citations
Peers
Hao‐Yuan Mo
Jingfeng Zong China
Shaojun Lin China
Yi‐Jun Hua China
Dong-Hua Luo China
Sing-Fai Leung China
Volkert B. Wreesmann United States
Peter M. L. Teo China
Hua-Qing Min China
G. B. Snow Netherlands
M.S. Kies United States
Citations per year, relative to Hao‐Yuan Mo Hao‐Yuan Mo (= 1×)
peers
Jingfeng Zong
Countries citing papers authored by Hao‐Yuan Mo
Since
Specialization
Citations
This map shows the geographic impact of Hao‐Yuan Mo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hao‐Yuan Mo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hao‐Yuan Mo more than expected).
Fields of papers citing papers by Hao‐Yuan Mo
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Hao‐Yuan Mo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hao‐Yuan Mo. The network helps show where Hao‐Yuan Mo may publish in the future.
Co-authorship network of co-authors of Hao‐Yuan Mo
This figure shows the co-authorship network connecting the top 25 collaborators of Hao‐Yuan Mo. A scholar is included among the top collaborators of Hao‐Yuan Mo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hao‐Yuan Mo. Hao‐Yuan Mo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Chen, Qiuyan, Hai‐Qiang Mai, Shan-Shan Guo, et al.. (2024). Induction-concurrent versus concurrent-adjuvant chemoradiotherapy in patients with high-risk N2–3 nasopharyngeal carcinoma: An open-label, randomised, controlled, phase 3 trial.. Journal of Clinical Oncology. 42(16_suppl). 6072–6072.
2.
Mai, Hai‐Qiang, Shanshan Guo, Li-Ting Liu, et al.. (2024). Neoadjuvant and adjuvant toripalimab for high-risk locoregionally advanced nasopharyngeal carcinoma: A randomized, double-blind, placebo-controlled phase 2 trial.. Journal of Clinical Oncology. 42(16_suppl). 6084–6084.
3.
Luo, Dong–Hua, Xiaoyun Li, Shanshan Guo, et al.. (2023). Paclitaxel liposome, cisplatin and 5-fluorouracil-based induction chemotherapy followed by de-escalated intensity-modulated radiotherapy with concurrent cisplatin in stage IVA–IVB childhood nasopharyngeal carcinoma in endemic area: a phase II, single-arm trial. The Lancet Regional Health - Western Pacific. 40. 100895–100895.
4.
Guo, Shanshan, Li‐Ting Liu, Qiuyan Chen, et al.. (2021). Prognostic significance of a combined and controlled nutritional status score and EBV-DNA in patients with advanced nasopharyngeal carcinoma: a long-term follow-up study. Cancer Biology and Medicine. 19(4). 551–564.
5.
Liu, Li‐Ting, Yu-Jing Liang, Shanshan Guo, et al.. (2020). Induction chemotherapy followed by radiotherapy versus concurrent chemoradiotherapy in the treatment of different risk locoregionally advanced nasopharyngeal carcinoma. Therapeutic Advances in Medical Oncology. 12. 3863543254–3863543254.
6.
Li, Jibin, Shanshan Guo, Lin‐Quan Tang, et al.. (2020). Longitudinal Trend of Health-Related Quality of Life During Concurrent Chemoradiotherapy and Survival in Patients With Stage II–IVb Nasopharyngeal Carcinoma. Frontiers in Oncology. 10. 579292–579292.
7.
Sun, Xuesong, Lin‐Quan Tang, Hai‐Qiang Mai, et al.. (2019). Combining pretreatment plasma Epstein‐Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma: A cohort study. Cancer Medicine. 8(16). 6841–6852.
8.
Hua, Xin, Qian Zhu, Wei Hu, et al.. (2018). Efficacy of controlled-release oxycodone for reducing pain due to oral mucositis in nasopharyngeal carcinoma patients treated with concurrent chemoradiotherapy: A prospective clinical trial. Annals of Oncology. 29. ix95–ix95.
9.
Zhang, Wangjian, Xiuyu Cai, Wayne R. Lawrence, et al.. (2018). The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era. Cancer Research and Treatment. 51(1). 34–42.
10.
Li, Peijing, Hao‐Yuan Mo, Dong–Hua Luo, Wei‐Han Hu, & Ting Jin. (2018). The efficacy of induction chemotherapy in the treatment of stage II nasopharyngeal carcinoma in intensity modulated radiotherapy era. Oral Oncology. 85. 95–100.
11.
Yao, Ji‐Jin, Siyang Wang, Wangjian Zhang, et al.. (2017). The Effect of Adding Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma and Undetectable Pretreatment Epstein-Barr Virus DNA. Translational Oncology. 10(4). 527–534.
12.
L, Hu, Wei‐Xiong Xia, Xing Lv, et al.. (2017). Concurrent chemoradiotherapy with 3-weekly versus weekly cisplatin in patients with locoregionally advanced nasopharyngeal carcinoma: A phase 3 multicentre randomised controlled trial (ChiCTR-TRC-12001979).. Journal of Clinical Oncology. 35(15_suppl). 6006–6006.
13.
Shen, Ting, Lin‐Quan Tang, Weiguang Gu, et al.. (2015). Plasma Epstein–Barr Viral Deoxyribonucleic Acid Predicts Worse Outcomes in Pediatric Nonmetastatic Nasopharyngeal Carcinoma Patients. Medicine. 94(50). e1945–e1945.
14.
Li, Peijing, Ting Jin, Dong–Hua Luo, et al.. (2015). Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma. PLoS ONE. 10(10). e0141332–e0141332.
15.
Li, Jiang, et al.. (2011). Immunophenotyping at the Time of Diagnosis Distinguishes Two Groups of Nasopharyngeal Carcinoma Patients: Implications for Adoptive Immunotherapy. International Journal of Biological Sciences. 7(5). 607–617.
16.
Liu, Yue, Qihong Huang, Wanli Liu, et al.. (2011). Establishment of VCA and EBNA1 IgA‐based combination by enzyme‐linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two‐stage design with a preliminary performance study and a mass screening in southern China. International Journal of Cancer. 131(2). 406–416.
17.
Li, Jiang, Hao‐Yuan Mo, Ulrika Rolén, et al.. (2007). Functional Inactivation of EBV-Specific T-Lymphocytes in Nasopharyngeal Carcinoma: Implications for Tumor Immunotherapy. PLoS ONE. 2(11). e1122–e1122.
18.
Mai, Hai‐Qiang, et al.. (2006). Elevated plasma big ET‐1 is associated with distant failure in patients with advanced‐stage nasopharyngeal carcinoma. Cancer. 106(7). 1548–1553.
19.
Mai, Hai‐Qiang, et al.. (2006). Therapeutic targeting of the endothelin a receptor in human nasopharyngeal carcinoma. Cancer Science. 97(12). 1388–1395.
20.
Ma, Jun, Hai‐Qiang Mai, Ming‐Huang Hong, et al.. (2001). Is the 1997 AJCC staging system for nasopharyngeal carcinoma prognostically useful for Chinese patient populations?. International Journal of Radiation Oncology*Biology*Physics. 50(5). 1181–1189.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Jingfeng Zong Breakdown of academic impact, for papers by Shaojun Lin Breakdown of academic impact, for papers by Yi‐Jun Hua Breakdown of academic impact, for papers by Dong-Hua Luo Breakdown of academic impact, for papers by Sing-Fai Leung Breakdown of academic impact, for papers by Volkert B. Wreesmann Breakdown of academic impact, for papers by Peter M. L. Teo Breakdown of academic impact, for papers by Hua-Qing Min Breakdown of academic impact, for papers by G. B. Snow Breakdown of academic impact, for papers by M.S. Kies